The development of small-molecule drugs that improve CFTR processing (correctors) in patients with Phe508del mutations, which would be beneficial for the vast majority of patients with CF, has so far proven more difficult (reviewed in Bell et al.24). The gene discussed is CFTR; the disease is cystic fibrosis.